Toward a stem cell gene therapy for breast cancer

Blood

Volumn 113, Issue 22, 2009, Pages 5423-5433

  Li, ZongYi ^a   Liu, Ying ^a   Tuve, Sebastian ^a   Xun, Ye ^b   Fan, Xiaolong ^c   Min, Liang ^b   Feng, Qinghua ^d   Kiviat, Nancy ^d   Kiem, Hans Peter ^a,e   Disis, Mary Leonora ^a   Lieber, André ^a,d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Shanghai Sunway Biotech Co Ltd   (China)

^c Lund Strategic Research Center for Stem Cell Biology and Cell Therapy   (Sweden)

^d UNIVERSITY OF WASHINGTON   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; RELAXIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL HOMING; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; GENE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RLX GENE; SCID MOUSE; STEM CELL GENE THERAPY; STROMA; TRANSGENE; ANIMAL; BREAST TUMOR; CELL CULTURE; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; METABOLISM; METHODOLOGY; MORTALITY; MOUSE MUTANT; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHYSIOLOGY; STROMA CELL; SURVIVAL; TRANSGENIC MOUSE;

ANIMALS; BREAST NEOPLASMS; CELLS, CULTURED; CHEMOTAXIS, LEUKOCYTE; FEMALE; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, SCID; MICE, TRANSGENIC; RELAXIN; STROMAL CELLS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67049164937     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-187237     Document Type: Article

References (42)

1. Kass L, Erler JT, Dembo M, Weaver VM. Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis. Int J Biochem Cell Biol. 2007;39:1987-1994. (Pubitemid 47369248)
2. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990;9:253-266.
3. Li ZY, Ni S, Yang X, Kiviat N, Lieber A. Xenograft models for liver metastasis: relationship between tumor morphology and adenovirus vector transduction. Mol Ther. 2004;9:650-657. (Pubitemid 38660417)
4. Pluen A, Boucher Y, Ramanujan S, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A. 2001;98:4628-4633. (Pubitemid 32295027)
5. Biswas SK, Gangi L, Paul S, et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 2006;107:2112-2122. (Pubitemid 43289397)
6. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 2007;67:5064-5066.
7. Ueno T, Toi M, Saji H, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000;6:3282-3289. (Pubitemid 30637758)
8. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211-217. (Pubitemid 40568680)
9. Kahl CA, Tarantal AF, Lee CI, et al. Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector. Exp Hematol. 2006;34:369-381.
10. Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Non-myeloablative transplants for malignant disease. Hematology Am Soc Hematol Educ Program. 2001:375-391.
11. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med. 2001;7:452-458. (Pubitemid 32298548)
12. Disis M-L, Knutson KL, Schiffman K, et al. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat. 2000;62:245-252. (Pubitemid 30804446)
13. Brown E, McKee T, diTomaso E, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 2003;9:796-800.
14. Kuriyama N, Kuriyama H, Julin CM, Lamborn K, Israel MA. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum Gene Ther. 2000;11:2219-2230. (Pubitemid 30826396)
15. Cheng J, Sauthoff H, Huang Y, et al. Human matrix metalloproteinase-8 gene delivery increases the oncolytic activity of a replicating adenovirus. Mol Ther. 2007;15:1982-1990. (Pubitemid 350011738)
16. Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res. 2007;67:10664-10668. (Pubitemid 350145891)
17. Sherwood OD. Relaxin's physiological roles and other diverse actions. Endocr Rev. 2004;25:205-234.
18. Van Der Westhuizen ET, Summers RJ, Halls ML, Bathgate RA, Sexton PM. Relaxin receptors - new drug targets for multiple disease states. Curr Drug Targets. 2007;8:91-104.
19. Bathgate RA, Lekgabe ED, McGuane JT, et al. Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis. Mol Cell Endocrinol. 2007.
20. Ganesh S, Gonzalez Edick M, Idamakanti N, et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. 2007;67:4399-4407. (Pubitemid 46815089)
21. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst. 2006;98:1482-1493. (Pubitemid 44605593)
22. Vrancken Peeters MJ, Perkins AL, Kay MA. Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques. 1996;20:278-285.
23. Tuve S, Chen BM, Liu Y, et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res. 2007;67:5929-5939. (Pubitemid 46985029)
24. Jonjic N, Valkovic T, Lucin K, et al. Comparison of microvessel density with tumor associated macrophages in invasive breast carcinoma. Anticancer Res. 1998;18:3767-3770. (Pubitemid 28564262)
25. Lu H, Knutson KL, Gad E, Disis ML. The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res. 2006;66:9754-9761. (Pubitemid 44623677)
26. Knutson KL, Dang Y, Lu H, et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol. 2006;177:84-91. (Pubitemid 43939119)
27. Emery DW, Nishino T, Murata K, Fragkos M, Stamatoyannopoulos G. Hematopoietic stem cell gene therapy. Int J Hematol. 2002;75:228-236. (Pubitemid 43014053)
28. Malik P, Arumugam PI, Yee JK, Puthenveetil G. Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator. Ann N Y Acad Sci. 2005;1054:238-249. (Pubitemid 43031030)
29. Bowman TV, Merchant AA, Goodell MA. Molecular profiling of hematopoietic stem cells. Methods Mol Med. 2007;134:1-16.
30. Azizi SA, Stokes D, Augelli BJ, DiGirolamo C, Prockop DJ. Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats-similarities to astrocyte grafts. Proc Natl Acad Sci U S A. 1998;95:3908-3913. (Pubitemid 28173227)
31. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002;62:3603-3608. (Pubitemid 34728832)
32. De Palma M, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med. 2003;9:789-795. (Pubitemid 36749231)
33. Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther. 2006;13:1031-1049. (Pubitemid 43779188)
34. Beard BC, Keyser KA, Trobridge GD, et al. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. Hum Gene Ther. 2007;18:423-434.
35. Wang H, Lieber A. A helper-dependent capsid-modified adenovirus vector expressing adeno-associated virus rep78 mediates site-specific integration of a 27-kilobase transgene cassette. J Virol. 2006;80:11699-11709. (Pubitemid 44788883)
36. Wang H, Shayakhmetov DM, Leege T, et al. A capsid-modified helper-dependent adenovirus vector containing the beta-globin locus control region displays a nonrandom integration pattern and allows stable, erythroid-specific gene expression. J Virol. 2005;79:10999-11013. (Pubitemid 41170641)
37. Nath CE, Shaw PJ. Busulphan in blood and marrow transplantation: dose, route, frequency and role of therapeutic drug monitoring. Curr Clin Pharmacol. 2007;2:75-91.
38. Silvertown JD, Ng J, Sato T, Summerlee AJ, Medin JA. H2 relaxin overexpression increases in vivo prostate xenograft tumor growth and angiogenesis. Int J Cancer. 2006;118:62-73. (Pubitemid 41681581)
39. Silvertown JD, Symes JC, Neschadim A, et al. Analog of H2 relaxin exhibits antagonistic properties and impairs prostate tumor growth. FASEB J. 2007;21:754-765. (Pubitemid 46348251)
40. Samuel CS, Hewitson TD, Unemori EN, Tang ML. Drugs of the future: the hormone relaxin. Cell Mol Life Sci. 2007;64:1539-1557.
41. Turley EA, Veiseh M, Radisky DC, Bissell MJ. Mechanisms of Disease: epithelial-mesenchymal transition-does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol. 2008;5:280-290.
42. Stearman RS, Dwyer-Nield L, Grady MC, Malkinson AM, Geraci MW. A macrophage gene expression signature defines a field effect in the lung tumor microenvironment. Cancer Res. 2008;68:34-43.